Development of Paclitaxel PBPK Model to Predict Tumour Concentration in Cancer Patients Poster Development of Paclitaxel PBPK Model to Predict Tumour Concentration in Cancer Patients CertaraJune 24, 2019
Mechanistic models of cancer Mechanistic models cancer-immune cycle and immunotherapies Poster Mechanistic models of cancer Mechanistic models cancer-immune cycle and immunotherapies CertaraJune 24, 2019
Integration of a Tumour Growth Inhibition Model within a Mouse Physiologically-Based Pharmacokinetic Model Poster Integration of a Tumour Growth Inhibition Model within a Mouse Physiologically-Based Pharmacokinetic Model CertaraJune 24, 2019
Optimize Immuno-oncology Drug Discovery and Development Using QSP White Paper Optimize Immuno-oncology Drug Discovery and Development Using QSP A Quantitative Systems Pharmacology (QSP) approach for developing combination immune-oncology therapies can be used to…CertaraJune 19, 2019
Population Pharmacokinetic Analysis of DS-8201a, A HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive Breast Cancer or Other Solid Tumors Poster Population Pharmacokinetic Analysis of DS-8201a, A HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive Breast Cancer or Other Solid Tumors CertaraMay 2, 2019
Simulating the Impact of the Interplay Between CYP2C19 Polymorphisms and Ethnicity on Response to Clopidogrel, Using PBPK-PD Models Poster Simulating the Impact of the Interplay Between CYP2C19 Polymorphisms and Ethnicity on Response to Clopidogrel, Using PBPK-PD Models CertaraApril 22, 2019
Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients Poster Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients CertaraApril 22, 2019
Relationship of Ivosidenib Plasma Concentration to Heart Rate-Corrected QT Interval in Patients with IDH1-Mutant Advanced Hematologic Malignancies Poster Relationship of Ivosidenib Plasma Concentration to Heart Rate-Corrected QT Interval in Patients with IDH1-Mutant Advanced Hematologic Malignancies CertaraApril 22, 2019
Validation of the Pharmacokinetic/Pharmacodynamic Model Used for Dose Selection of Andexanet Alfa for Reversal of Anticoagulation Poster Validation of the Pharmacokinetic/Pharmacodynamic Model Used for Dose Selection of Andexanet Alfa for Reversal of Anticoagulation CertaraApril 22, 2019
Development of a Pre-clinical Quantitative Systems Pharmacology Model for E7046, a Novel PGE2 Receptor Type 4 Antagonist for Cancer Immunotherapy Poster Development of a Pre-clinical Quantitative Systems Pharmacology Model for E7046, a Novel PGE2 Receptor Type 4 Antagonist for Cancer Immunotherapy CertaraOctober 8, 2018